Intervention not reported
Interferon beta‐1b (Betaferon) (Direct evidence; 2 RCTs; 403 participants)
It is very uncertain whether the intervention changes interferon beta‐1b (Betaferon) (Direct evidence; 2 RCTs; 403… (very low certainty).
1 finding from 1 review
RR 0.86 [0.67, 1.11]
1 study · 2 participants
Very low
Interferon + SSA (2 RCTs; 171 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon + SSA (2 RCTs; 468 participants) compared with placebo (very low certainty).
4 findings from 1 review
HR 0.34 [0.14, 0.8]
2 studies · 468 participants
Very low
OR 5.71 [1.9, 17.2]
4 studies · 283 participants
Very low
HR 0.23 [0.06, 0.93]
3 studies · 512 participants
Very low
Show 1 more finding
Interferon (1 RCT; 66 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon (1 RCT; 66 participants) compared with placebo (very low certainty).
4 findings from 1 review
HR 0.41 [0.18, 0.94]
1 study · 66 participants
Very low
OR 4.03 [0.86, 18.8]
2 studies · 86 participants
Very low
HR 0.27 [0.07, 1.1]
1 study · 66 participants
Very low
Show 1 more finding
Interferons or glatiramer acetate · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes interferons or glatiramer acetate compared with other disease‐modifying treatments (very low certainty).
1 finding from 1 review
HR 0.86 [0.52, 1.42]
853 participants
Very low
Interferon beta or glatiramer acetate · relapsing multiple sclerosis
Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).
2 findings from 1 review
OR 1.71 [1.11, 2.62]
5477 participants
Moderate
HR 0.14 [0.05, 0.39]
335 participants
Moderate
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Chronic HCV infection†‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin… compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (proportion) ‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (number) ‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
Intervention not reported
Interferon (B) versus inactive control (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Very low
Intervention not reported
Interferon (B) versus antiviral (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Low
Intervention not reported
Interferon + antiviral (B) versus antiviral (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Debridement + antiviral or interferon (B) versus debridement (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Interferon vs. control · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Interferon vs. control · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Peg interferon vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes peg interferon vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Peg interferon plus ribavirin vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes peg interferon plus ribavirin vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Ribavirin plus peg interferon vs.peg interferon · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes ribavirin plus peg interferon vs.peg interferon (very low certainty).
1 finding from 1 review